Document is current
Any future updates will be listed below
-
Authors
Yu, Haiyang
Wei, Jingjing
Chen, Qinhao
Pan, Yueyin
Qian, Xiaojun
Pan, Jing
Sun, Yubei
-
Funding
Funding for this research was provided by:
National Natural Science Funds of China (82172775)
National Key Clinical Specialty Construction Project 2021 Oncology (2021GJLC01)
Anhui Province Cancer Bioimmunotherapy Clinical Medical Research Center (202101B10202005)
Breast cancer precision tumor research and innovation team (2022AH010077)
Beijing Science and Technology Innovation Medical Development Foundation Project (KC2021-JF-0167-23)
- License Information
-
More Information
Article History
Received: 22 July 2024
Accepted: 2 May 2025
First Online: 10 June 2025
Declarations
:
: The present study was approved by the Ethics Committee of Anhui Provincial Hospital (No. 2022-ZNW-02), and all patients gave informed consent. This study was reviewed and approved by the University of Science and Technology of China Animal Experimentation Ethics Committee (No. USTCACUC192401041). All procedures of animal study were performed according to the protocols approved by the Institutional Animal Ethics Care and Use Committee of the University of Science and Technology of China. According to the Ethics Committee, the maximum tumor size must not exceed 20 mm in any direction in an adult mouse, and in our experiment, the maximal tumor size remained within this limit.
: The authors declare no competing interests.
